Gossamer Bio Inc. (GOSS) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Gossamer Bio Inc. (GOSS) Misses Q2 EPS by 4c

Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 9, 2021 4:01 PM EDT

- Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively -

- Gossamer Announces Seralutinib Open Label Extension Data in PAH Patients -

- Gossamer to Discontinue Clinical Development of GB1275 -

- Cash, cash equivalents and marketable securities totaled $406 million as of June 30, 2021 -

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing... More